Abstract
Hypertension is a significant risk factor for cardiovascular and cerebrovascular diseases and the leading cause of premature death worldwide. However, the pathogenesis of the hypertension, especially essential hypertension, is complex and requires in-depth studies. Recently, new findings about essential hypertension have emerged, and these may provide important theoretical bases and therapeutic tools to break through the existing bottleneck of essential hypertension. In this review, we demonstrated important advances in the different pathogenesis areas of essential hypertension, and highlighted new treatments proposed in these areas, hoping to provide insight for the prevention and treatment of the essential hypertension.
Introduction
Hypertension is characterized by a rise in systolic blood pressure (BP) and/or diastolic BP. The diagnostic criteria recommended in different guidelines for hypertension vary from each other in most major guidelines, it is recommended that hypertension be diagnosed when a person’s SBP in the office or in the clinic is ≥140 mmHg and/or DBP is ≥90 mmHg following repeated examinations (1). Hypertension is a significant risk factor for cardiovascular and cerebrovascular diseases (CVDs) and is the leading cause of premature death worldwide (2). The estimated prevalence of hypertension in the global adult population was 31.1% (1.39 billion) in 2010 and is still on the rise (2). Preventing and controlling hypertension is a major global public health strategy for reducing premature mortality from CVDs (3). Depending on whether a clear cause can be found, hypertension is divided into two categories: essential (primary) hypertension without a definite cause and secondary hypertension with a definite cause.
Essential hypertension accounts for more than 90% of all hypertensive patients (1), but the exact underlying mechanisms remain ambiguous. The present treatment of essential hypertension mainly based on long-term BP control but not curing the disease, which relies a lot on the patient’s financial status and adherence to treatment (4). Therefore, the investigation of the causative mechanism has been the key research direction of essential hypertension. There are two factors that affect BP directly, including vasodilation capacity and the volume of intravascular fluid. Vasodilatation capacity is affected by vascular elasticity, caliber, and reactivity, which reflects the buffering capacity of vessels against pressure shocks. Poorer the vasodilatation capacity, higher the BP. Volume of intravascular fluid is regulated by the body’s intake and elimination of fluid. Once the fluid balance is disturbed, the increase in the amount of intravascular fluid can directly result in an increase in BP. Therefore, factors that cause increases in blood volume or decreases in vasodilatation capacity can lead to hypertension. These factors usually coexist and are intertwined with each other in the occurrence and progress of essential hypertension. The lack of appropriate clinical identification methods currently brings difficulties into making proper treatment plans for hypertensive patients.
The most commonly applied method of controlling hypertension is pharmacological treatment based on lifestyle intervention. The three main antihypertensive medication are renin-angiotensin-aldosterone system (RAAS) inhibitors, calcium channel antagonists and diuretics, from which a variety of single-pill combinations have been derived (5–7). Currently, a lot of new findings about essential hypertension have emerged, and these provide important theoretical evidence to help develop a better understanding and treatment of essential hypertension. In this review, we briefly reviewed advances in pathogenesis and intervention methods of essential hypertension in recent years.
Arterial stiffness
Arterial stiffness refers to a reduction in elasticity and distensibility of arteries, and pulse wave velocity (PWV) is often used to represent the degree of stiffness in large arteries. An increase in PWV indicates severe arterial stiffness and impaired in arterial dilatation capacity (8). Arterial stiffness has been closely associated with an increased risk of essential hypertension (9, 10), especially the isolated systolic hypertension (11). Vice versa, systolic BP is also associated with a clinically significant progression of arterial stiffness (12). It is still a “chicken and egg question” that elevated blood pressure and arterial stiffness which come first.
Arterial stiffness can be classified into functional arterial stiffness and structural arterial stiffness (13). Functional arterial stiffness is mainly related to the contractile function of vascular smooth muscle cells (VSMCs) which is influenced by a variety of factors (Figure 1). Among them, an increase in intracellular calcium ion (CA2+) concentration can directly influence VSMCs. And calcium channel blockers (CCBs), which are widely used in clinical settings, are to reduce intracellular calcium concentration in SMCs (14) and thus controlling BP. The nitric oxide (NO)-nitric oxide-sensitive guanylate cyclase (NOsGC)-cGMP pathway is also a well-studied pathway that is closely related to the contractile function of VSMCs. NO-NOsGC-cGMP pathway begins in vascular endothelial cells and regulates VSMCs contraction through a series of signaling (15–17). Injectable antihypertensive drugs, such as sodium nitroprusside and nitrates, all exert their vasodilatory effects through the NO-NOsGC-cGMP pathway.
FIGURE 1
Factors influencing the contractile function of smooth muscle cells. Ox-LDL, Oxidized low-density lipoprotein; TGs, Triglycerides; UPR, unfolded protein response; KLF4, Krüppel-Like Factor 4.
Structural arterial stiffness is closely associated with age, hyperlipidemia, diabetes mellitus, and is characterized by elastin disruption, collagen deposition, and altered extracellular matrix composition (11, 13). However, unlike functional arterial stiffness, there is no effective treatment for structural arterial stiffness yet, since pathological changes in structural arterial stiffness are difficult to reverse. The phenotypic transition of VSMCs directly affects the structural arterial stiffness. Six phenotypes of VSMCs have been reported currently, out of which the contractile phenotype is rich in a-smooth muscle actin (a-SMA) and has the strongest contractile function. When VSMCs switch from contractile to other phenotypes (such as macrophage-like phenotype), the contractile function of the cells decreases significantly (18–20). Krüppel-Like Factor 4 (KLF4) is thought to be a key target in regulating the conversion of contractile VSMCs to other phenotypes (20). However, most of the current studies showed an important role of KLF4 in pulmonary hypertension (21–23), while it is not clear whether KLF4 in VSMCs is associated with essential hypertension.
Water-sodium retention and salt-sensitive
Water-sodium retention is a key cause of abnormal increases in intravascular fluid volume. Diuretics (especially thiazide diuretics) are important in the control of hypertension caused by water-sodium retention (24). Except secondary hypertension resulted from renal dysfunction, there is also a group of hypertensive patients related to water-sodium retention in essential hypertension, namely salt-sensitive hypertension.
High-salt intake is an important trigger in essential hypertension caused by water-sodium retention. Not all people will develop increased BP after consuming excessive salt. According to the blood pressure reactivity to salt-intake, patients are called salt-sensitive and salt-resistant, respectively (25). Multiple factors may contribute to the development of salt-sensitive hypertension, including age, obesity, genetic background, and maternal conditions during fetal life etc. (26), but the underlying mechanisms of salt-sensitive hypertension are not fully understood. Studies showed that low potassium activates (turns on) the system by hyperpolarizing the membrane, thereby driving Cl– out of the cell and off the inhibitory binding site on WNK (with no lysine [K]) kinases. Once disinhibited, WNK kinases phosphoactivate SPAK (STE20/SPS1-related proline/alanine–rich kinase), which in turn phosphoactivates nine–rich kinase co-transporter (NCC), and this called the Potassium Switch theory (27–29), which is one of the important theories on the pathogenesis of salt-sensitive hypertension. Recently, increasing evidence showed that intestinal flora is closely associated with salt-sensitive hypertension (30, 31) (Figure 2). The fecal microbiota of healthy rats could significantly lower BP in high-salt diet induced hypertensive (hSIH) rats, whereas the fecal microbiota of hSIH rats had opposite effects (32). Adoptive transfer of fecal material from conventionally housed high-salt diet–fed mice to germ-free mice predisposed them to increased inflammation and hypertension, the reason for this result may associated with an increase in Firmicutes, Proteobacteria, and genus Prevotella bacteria (33). The underlying mechanisms for intestinal flora to lead to increased BP are still under investigation. There is evidence that high-salt intake depleted Lactobacillus to induce T helper 17 cells and to promote hypertension (34). Another study demonstrated that high-salt dietry reduced the levels of B. fragilis and arachidonic acid in the intestine, which increased intestinal-derived corticosterone production and corticosterone levels in serum and intestine, thereby promoting BP elevation (32). In deoxycorticosterone acetate (DOCA)–salt mice model of hypertension, short-chain fatty acids released by the fermentation of fiber from the intestinal flora are associated with lower BP levels, and this may be closely related to the increase in Bacteroides acidifaciens (35). Notably, the intestinal flora is not only involved in salt sensitivity, it also participate in other underlying mechanisms of hypertension (36), including RAAS (37–39), vascular endothelium (40), and renal dysfunction (41) etc. A recent large intestinal flora sequencing study demonstrated the role of intestinal flora in human was extremely complex (42). Intestinal flora also has the potential to be an independent mechanism of essential hypertension.
FIGURE 2
High salt intake triggers high blood pressure through intestinal flora.
Reducing sodium intake has been considered as an important way to reduce the incidence of hypertension (43–45). However, the benefits of using salt with low doses of sodium remain controversial, since low sodium intake is also associated with an increased risk of cardiovascular disease (46, 47). Great progress has been made in application of salt substitution recently. Excessive sodium intake leads to an increase in circulating fluid, which raises BP. While potassium intake has a diuretic effect, which reduces circulating fluid (48). Both dietary sodium reduction and dietary potassium supplementation have shown clear BP–lowering effects in clinical studies (45, 49). In addition, according to the Potassium Switch theory, even high sodium intake, low dietary potassium still increases salt sensitivity (27). Salt substitution reduces sodium chloride and increases potassium chloride, thus exerting its antihypertension effects (50). There are two main types of salt substitution used in current clinical studies. One contains only sodium chloride and potassium chloride (51, 52), and the other one contains magnesium sulfate in addition to sodium chloride and potassium chloride (53, 54). Studies have demonstrated that both types of salt substitution not only lower BP but also reduce cardiovascular events in patients (51, 53–56). Additionally, the use of sodium and potassium salts (75% sodium chloride and 25% potassium chloride by mass) has therapeutic effects, as well as good economic benefits (55). Based on the results of these studies, it is very likely that salt recommendations for people 4, especially for hypertensive patients, will change in the near future. And to achieve the popularization of salt substitutes, the benefits of salt substitution need to be spread across the population (57).
Renin-angiotensin-aldosterone system
Renin-angiotensin-aldosterone system is a consecutive peptidergic system that functions in the control of the renal, adrenal, and cardiovascular systems. RAAS regulates BP mainly by affecting arterial constriction and water-sodium retention in the body. Both circulating RAAS and tissue RAAS (cardiac RAAS, vascular RAAS, intra-renal RAAS, brain RAAS and adipose tissue RAAS) have been involved in the pathogenesis of essential hypertension and related target organ damage (58). Several components of axis cascade have been identified in the RAAS, including angiotensinogen, renin, angiotensin-converting enzyme, angiotensins with various subtypes (Ang I, Ang II, Ang III, Ang IV, Ang 1-7), aldosterone and aldosterone receptors. Among these, angiotensinogen, produced by the liver, is the starting point of the system. Angiotensinogen is cleaved by renin secreted from the kidney to form angiotensin I. Angiotensin I (1-10) is then cleaved in the circulatory system by enzymes (e.g., Angiotensin converting enzyme) to form different peptides that eventually act in various organs (59). Among these cleavage peptides, the function of angiotensin II (1-8) has been elucidated the most. Angiotensin II binds to angiotensin II receptor (also classified as type 1,2) in several organs and directly leads to vasoconstriction, water-sodium retention, and myocardial remodeling. In addition, when angiotensin II acts on the kidney, it further stimulates aldosterone secretion and exacerbates water-sodium retention (60).
RAAS inhibitors are one of the three cornerstones of existing antihypertension medications, and are also the drugs of first-line option for hypertensives with target organ damage (e.g., heart failure, mild-to-moderate renal failure). Clinical trials have demonstrated that RAAS blockades, including angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor (formally referred to sybtype-1 receptor, AT1R) blockers (ARBs), Angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor blockers (MRAs), contributes to the prevention of hypertension as well as the protection of target organs (1). In addition to oral drug therapies, hypertension vaccines developed for the RAAS system have become increasingly attractive in recent years (Table 1). The first hypertension vaccine has been studied for more than 30 years (61), and related studies are still ongoing. Compared with drug therapy, this immunotherapeutic approach to treating of hypertension have the potential to improve health outcomes, reduce healthcare costs, and increase medication adherence, since it can induce prolonged therapeutic effects and requires low frequency of administration. Currently, hypertension vaccines mainly target RAAS. Renin vaccines are the first vaccines developed. However, this vaccine has the risk of causing autoimmune diseases (61, 62), and in clinical studies, renin inhibitors do not provide long-term cardiovascular and renal protective effects despite their ability to lower BP (63, 64). Therefore, the future of renin vaccine to be used in clinic is not optimistic. Except for renin, other vaccines targeting Ang I, Ang II, AT1R, etc. have lowered BP at animal level without significant side effects. So far only CYT006-AngQb, an Ang II Vaccine, has obtained results in clinical phase II studies (65). However, it is worth mentioning that the clinical use of RAAS inhibitors is already very mature and painless, while vaccines may be cause pain and require repeated injections (65), which may discourage some patients from trying vaccine therapy. A recent study reported a non-RAAS-targeted vaccine, short peptide ADR-004 (cgiteeagy), screened from α1D-adrenoceptor (α1D-AR), not only effectively lowered BP, but also showed target organ protection after injection into spontaneous hypertension rats. This ADRQβ-004 vaccine targeting α1D-AR is expected to solve problems of low subtype selectivity and short half-life of α1-AR blockers in current clinical use (66).
TABLE 1
| Target | Drug type | Studied subject | Results | Representative study |
| Renin | Heterologous renin (antibodies are produced in vivo) | Monkeys | Reduced BP in monkeys, but induced renal autoimmune diseases. | (61) |
| Renin-derived Peptides (antibodies are produced in vivo) | Rats | Reduced BP in rats with no side effects. | (121). | |
| Angiotensin I (Ang I) | Ang I-derived peptides | Rats | Reduced BP and Ang I levels in rats, with no effects on Ang II and no side effects. | (122) |
| Ang I-derived peptides | Human (Phase I) | Reduced Ang I levels but failed to reduce BP. | (123) | |
| Angiotensin II (Ang II) | Ang II-derived active peptides | Population (Phase II) | Reduced BP with no side effects. | (65) |
| DNA fragment of Ang II (antibodies are produced in vivo) | Rats | Reduced BP in rats with no side effects. | (124) | |
| Ang II-derived peptides | Rats | Reduced Ang II levels in rats but failed to reduce BP. | (125) | |
| Angiotensin II Type-1 Receptor (AT1R) | AT1R-derived peptides | Rats | Reduced BP in rats with no side effects. | (126) |
| α-1D-Adrenergic Receptor (α1-AR) | α1-AR-derived peptides | Rats | Reduced BP and protected target organs in rats with no side effects. | (66) |
Hypertension vaccines.
Sympathetic dysregulation
Sympathetic dysregulation is also an important cause of essential hypertension (67). The sympathetic overdrive leads to increased cardiac output, increased systemic vascular tone, and elevated plasma catecholamine levels. Patients with hypertension can manifest as greater muscle sympathetic nerve activity (MSNA) and lower baroreflex response (68).
Sympathetic hypertension varies widely among individuals and often associated with circadian patterns and mental status. MSNA plays a significant role in determining total peripheral resistance and vasoconstrictive function by controlling skeletal muscle (69). And MSNA may be a key cause of the huge individual variability in sympathetic hypertension, since studies have demonstrated that transduction of MSNA into vascular tone varies with age and sex (70, 71), and there is a close association of MSNA with attended (observed) and unattended (unobserved) BP levels in essential hypertension (72). The manifestations of BP changes in sympathetic hypertension are also complex, including morning hypertension, nocturnal hypertension, sleep apnea–related hypertension, orthostatic hypertension, resistant hypertension, etc., which may all be associated with autonomic dysregulation (73). Sympathetic overdrive not only contributes to the progression of BP elevation but also promotes hypertension-related target organ damage, such as left ventricular hypertrophy and dysfunction, congestive heart failure, renal insufficiency (73). Beta-blockers are drugs commonly used clinically for beta-adrenergic receptor action, which can inhibit the increase in BP and heart rate caused by sympathetic excitation. However, compared with other antihypertensive agents, such as diuretics, ACEi, ARB and CCBs, beta-blockers appear to be less protective against stroke and overall mortality, and are more often used as additional drugs for hypertensive patients (74). Exercise is an important way of controlling sympathetic hypertension, and studies have confirmed that high-intensity interval training (e.g., three 60-min exercise sessions per week for 4 months) can reduce BP by reducing MSNA (75, 76).
Renal denervation (RDN) has emerged as a potential treatment for resistant hypertension caused by sympathetic dysregulation. Renal sensory afferent nerve activity directly influences sympathetic outflow to the kidneys and other highly innervated organs involved in cardiovascular control. Abrogation of renal sensory afferent nerves reduces both BP and organ-specific damage caused by chronic sympathetic overactivity in various experimental models (77). Catheter-based radiofrequency denervation of the renal arteries is currently the most widely used technique for RDN, and RDN is gradually gaining recognition for its safety and antihypertensive effect (78–82), there are many RDN-related clinic trials ongoing (Table 2).
TABLE 2
| Identifier | Participants number | Location | Conditions | Model description | Primary outcome measures | Status |
| NCT04264403 | 80 | Germany | Uncontrolled Hypertension with CKD stage3 | prospective, double-blind, multi-center, randomized | Change in systolic 24-h ambulatory BP | Ongoing |
| NCT04060641 | 30 | United States, Texas | Hypertension | retrospective, observational, cohort | Correlation between genetic scoring and RDN effectiveness using office BP and AMBP | Ongoing |
| NCT05234788 | 90 | China | Uncontrolled Hypertension | prospective, open label, parallel assignment, multi-center, randomized | Reduction of office systolic blood pressure at 3 months. | Ongoing |
| NCT05198674 | 1200 | United States, Georgia; Germany | Uncontrolled Hypertension | open label, single-group assignment | Subgroup CKD: change in office SBP Subgroup isolated systolic hypertension: change in office systolic blood pressure change at 6 months Subgroup T2DM: change in office systolic blood pressure change at 6 months | Ongoing |
| NCT05326230 | 154 | Japan | Hypertension | double-blind, parallel assignment, randomized | Mean change in 24-hour systolic ABPM | Ongoing |
| NCT04314557 | 20 | Spain | Hypertension with sympathetic dysautonomia etc. | prospective, observational | Change of SBP in orthostatism | Ongoing |
| NCT05027685 | 3000 | Germany | Hypertension | multi-center, observational | 1. Incidence of all-cause mortality, 2. Reduction in average home and office systolic/diastolic BP as compared to enrollment; 3. Reduction in average ambulatory systolic/diastolic BP (daytime, nighttime and 24-h); etc. | Ongoing |
| NCT01673516 | 60 | Norway | Uncontrolled Hypertension | open label, parallel assignment, randomized | Absolute change in office SBP | Ongoing |
| NCT02772939 | 80 | Germany | Uncontrolled Hypertension | open label, single-group assignment | Predictive value of invasive PWV for BP response after renal denervation; Predictive value of non-invasive and invasive measures of in combination with clinical variables | Ongoing |
Ongoing clinical trial of RDN for hypertension.
RDN, Renal denervation; CKD, Chronic kidney disease; BP, Blood pressure; AMBP, Ambulatory blood pressure; T2DM, Diabetes mellitus type 2; SBP, systolic blood pressure; PWV, Pulse wave velocity.
Genetics
Hypertension is closely associated with genes, and our understanding of the relationship between genetics and BP has been well improved in recent years. More than 500 loci nvolved in the regulation of BP have been revealed by genome-wide association studies, taking the total number of BP genetic loci to over 1,000 (83–87). And BP is even discussed as a probable omnigenic trait (84). However, the identification of a true causal variant and its relevant gene product impacted is rarely straightforward. The lead single nucleotide polymorphism (SNP) typically indicates a chromosomal region usually with tens and sometimes thousands of SNPs in LD (88), but it may also mark further-away regions with long-range chromatin interactions (83, 89). Therefore, these SNPs often occur in non-protein coding regions of the genome and do not alter protein function are common, which lead a small effect on BP. Although SNPs provide a potential pathogenic mechanism for essential hypertension, there are few reported targets that have been successfully translated into clinical use. A recent study showed multiple SNP analyzed as a polygenic risk score (PRS) was predictive of early-onset hypertension in a progressive fashion, those with the highest of 2.5% of PRS had an almost 3-fold risk of developing hypertension, whereas a low PRS was protective (90). Proper use of SNPs may provide potential ways to diagnosis and treatment of hypertension.
Genetics alone is not sufficient to explain the variability in BP, suggesting that other risk factors are involved, such as epigenetic modifications. Emerge evidence demonstrated potential contribution of epigenetic mechanisms in essential hypertension. Genome-wide DNA methylation has been associated with susceptibility to hypertension in human (87, 91), and DNA methylation regulates several genes relevant to BP regulation, which have been proved in animal models (92, 93). In addition to DNA methylation, RNA methylation may also contribute to essential hypertension (94). Recent studies have demonstrated that N6-methyladenosine (m6A) -SNPs are enriched among the SNPs that are associated with BP, and approximately 10% of the BP-associated m6A SNPs are associated with coronary artery disease or stroke (95). However, the specific role of these RNA methylation sites in the pathogenesis of hypertension remains to be further studied. Other epigenetic modification, including post-translational histone modifications, non-coding RNAs and etc., also have been thought to be a promising study area for the development of novel future strategies for essential hypertension prevention and treatment (96, 97).
Interactions between the pathogenesis of hypertension
An updated Mosaic Theory has been proposed to explain the pathogenesis of hypertension, in which hypertension is considered as a response to different combinations of traits and stressors (98). In addition to vascular function, salt intake, sympathetic activation, genetics, microbiome, renal mechanisms, the new Mosaic Theory also highlights inflammation and oxidative stress (98). The interplay of these factors leads to a net-like pathogenesis of essential hypertension and increases the difficulty of the treatment.
In our opinion, the pathogenesis of hypertension is based on both decreased vasodilation and increased blood volume. Arterial stiffness directly causes a decrease in vasodilation, and water-sodium retention directly leads to an increase in blood volume. Additional factors such as RAAS, sympathetic system, and genes affect both vasodilation and blood volume (Figure 3A). Furthermore, there are complex interactions among those factors in the pathogenesis of hypertension. As a congenital factor, genes can simultaneously affect RAAS (59, 99–101), water-sodium retention (102), arterial stiffness (103), and sympathetic nerves (104). In the meantime, mutual effects also exist between RAAS, water-sodium retention, arterial stiffness and sympathetic nerves (105–108, Figure 3B).
FIGURE 3
Interaction between the pathogenesis of hypertension. (A) Causes of elevated blood pressure by different pathogenesis. (B) Interaction between pathogenic mechanisms.
Circulating biomarkers
Biomarkers for patient classification, risk stratification and monitoring of response to therapy is an important integral component of diseases diagnosis and treatment. Several novel measurable circulating biomarkers have been identified as a possible screening method to define the risk of hypertension development in the last years. Study showed that administering Pentraxin 3 (PTX3) to wild-type mice induced endothelial dysfunction and increased blood pressure, while the effect was not observed in P-selectin–deficient mice (109). Moreover, compared with normotensive subjects, hypertensive patients have higher plasma levels of PTX3 and its mediators P-selectin and matrix metalloproteinase-1 (MMP1, regulated by PTX3) (109). This suggests that the combination of PTX3, P-selectin and MMP-1 may be a novel biomarker for predicting the onset of vascular dysfunction in hypertensive patients. Sortilin, a member of the vacuolar protein sorting 10 (VPS10P) family of receptors, has been positively correlated with vascular and metabolic disorders (110). A recent study demonstrated that sortilin induced endothelial dysfunction of mesenteric arteries through NADPH oxidase 2 (NOX2) isoform activation, and the dysfunction could be prevented by knockdown of acid sphingomyelinase (ASMase) or sphingosine kinase 1 (111). Furthermore, plasma ASMase activity and plasma levels of sortilin increased in hypertensive subjects, especially in those with uncontrolled blood pressure (111). Therefore, the high levels of circulating sortilin may be helpful to explain the resistance to the anti-hypertensive pharmacological treatment. Some other biomarkers have also been reported in recent years, including Sphingosine-1-phosphate (112), bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) (113), klotho (114), exosomal microRNAs (such as miR-130a, miR-195.) (115), SUV420H1 (116), etc., which are considered to have the potential in hypertension predicting or evaluating.
In addition to revealing the underlying mechanism or evaluating the state of hypertension, these markers also have the potential to classify essential hypertension due to biomarkers’ specificity. For instance, PTX3 or sortilin is related to vascular dysfunction, while SUV420H1 is identified as a potential biomarker for the early diagnosis of salt-sensitive hypertension. These specific sources of markers may provide guidance for targeted treatment of hypertension with different pathogenesis.
Summary
Hypertension is a disease named after its clinical features, which is doomed to the diversity of its pathogenesis. Unlike secondary hypertension with determined causes, the underlying mechanisms of essential hypertension have not been fully elucidated yet. The complicated mechanisms and poor understanding make it difficult to cure essential hypertension.
At present, there are two main research directions to further optimize the treatment of hypertension (Figure 4). One is to sort out this net and separate out the role of each individual factor. For example, recent studies have proposed new clinical indicators to estimate augmented MSNA in hypertensive subjects, independent of the volume of the conducting vessels (117, 118). The results, to some extent, dissociated the cross of arterial stiffness and sympathetic dysregulation. Besides, as mentioned above, taking advantage of circulating biomarkers may also guide a more precise treatment. Another direction is oriented toward lowering BP without exploring too deeply into the mechanisms. Several new approaches are being proposed, which have been shown to lower BP by a variety of mechanisms. Taking RDN as an example, it not only interrupts the sympathetic-mediated neurohormonal pathway, but may also reduce plasma renin activity and aldosterone levels to inhibited RAAS (119, 120). As the complicated mechanisms of essential hypertension are not likely to be sort out in the near future, it is also of great significance for clinicians to shift their focus to treatment efficacy to meet the clinical needs.
FIGURE 4
Main research directions to further optimize the treatment of hypertension. (A) Sort out the net and separate out the role of individual factors. (B) Focus on clinical antihypertensive effect.
In summary, the reason why essential hypertension is difficult to cure is largely due to the pathogenesis which has not been fully elucidated and the factors leading to the pathogenesis of hypertension are intertwined. Continued in-depth mechanism study, especially the application of cutting-edge theories to the pathogenesis of hypertension, will be of great help in overcoming existing difficulties. On the other hand, optimizing the existing antihypertensive methods with blood pressure as the core goal is an important research direction for the clinical treatment of hypertension.
Statements
Author contributions
JM was responsible for the conception and writing of the article. XC was responsible for critical revisions. Both authors contributed to the article and approved the submitted version.
Funding
This study was funded by the National Natural Science Foundation of China (Nos. 81900404 and 81970355).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
UngerTBorghiCCharcharFKhanNAPoulterNRPrabhakaranDet al2020 international society of hypertension global hypertension practice guidelines.Hypertension. (2020). 75:1334–57. 10.1161/HYPERTENSIONAHA.120.15026
2.
MillsKTStefanescuAHeJ. The global epidemiology of hypertension.Nat Rev Nephrol. (2020) 16:223–37. 10.1038/s41581-019-0244-2
3.
SudharsananNTheilmannMKirschbaumTKManne-GoehlerJAzadnajafabadSBovetPet alVariation in the proportion of adults in need of blood pressure–lowering medications by hypertension care guideline in low- and middle-income countries.Circulation. (2021) 143:991–1001. 10.1161/CIRCULATIONAHA.120.051620
4.
FangJChangTWangGLoustalotF. Association between cost-related medication nonadherence and hypertension management among us adults.Am J Hypert. (2020) 33:879–86. 10.1093/ajh/hpaa072
5.
ParatiGKjeldsenSCocaACushmanWCWangJ. Adherence to single-pill versus free-equivalent combination therapy in hypertension.Hypertension. (2021) 77:692–705. 10.1161/HYPERTENSIONAHA.120.15781
6.
CampanaECunhaVGlaveckaiteSGruevILamiraultGLehmannEet alThe use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice.J Hypertens. (2020) 38:2369–77. 10.1097/HJH.0000000000002598
7.
TsioufisKKreutzRSykaraGvan VugtJHassanT. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature.J Hypert. (2020) 38:1016–28. 10.1097/HJH.0000000000002381
8.
SegersPRietzschelERChirinosJA. How to measure arterial stiffness in humans.Arterioscl Throm Vasc Biol. (2020) 40:1034–43. 10.1161/ATVBAHA.119.313132
9.
KaessBMRongJLarsonMGHamburgNMVitaJALevyDet alAortic stiffness, blood pressure progression, and incident hypertension.JAMA. (2012) 308:875–81. 10.1001/2012.jama.10503
10.
DumorKShoemaker-MoyleMNistalaRWhaley-ConnellA. Arterial stiffness in hypertension: an update.Curr Hypertens Rep. (2018) 20:72. 10.1007/s11906-018-0867-x
11.
ChirinosJASegersPHughesTTownsendR. Large-artery stiffness in health and disease: jacc state-of-the-art review.J Am Coll Cardiol. (2019) 74:1237–63. 10.1016/j.jacc.2019.07.012
12.
WilsonJWebbAJS. Systolic blood pressure and longitudinal progression of arterial stiffness: a quantitative meta-analysis.J Am Heart Assoc. (2020) 9:e017804–017804. 10.1161/JAHA.120.017804
13.
ZanoliLBrietMEmpanaJPCunhaPGMäki-PetäjäKMProtogerouADet alVascular consequences of inflammation: a position statement from the esh working group on vascular structure and function and the artery society.J Hypertens. (2020) 38:1682–98. 10.1097/HJH.0000000000002508
14.
TocciGBattistoniAPasseriniJMusumeciMBFranciaPFerrucciAet alCalcium channel blockers and hypertension.J Cardiovas Pharmacol Ther. (2014) 20:121–30. 10.1177/1074248414555403
15.
KraehlingJRSessaWC. Contemporary approaches to modulating the nitric oxide–cgmp pathway in cardiovascular disease.Circ Res. (2017) 120:1174–82. 10.1161/CIRCRESAHA.117.303776
16.
GarciaVSessaWC. Endothelial nos: perspective and recent developments.Br J Pharmacol. (2019) 176:189–96. 10.1111/bph.14522
17.
FarahCMichelLYMBalligandJL. Nitric oxide signalling in cardiovascular health and disease.Nat Rev Cardiol. (2018) 15:292–316. 10.1038/nrcardio.2017.224
18.
SanyourHJLiNRickelAPChildsJDKinserCNHongZ. Membrane cholesterol and substrate stiffness co-ordinate to induce the remodelling of the cytoskeleton and the alteration in the biomechanics of vascular smooth muscle cells.Cardiovasc Res. (2019) 115:1369–80. 10.1093/cvr/cvy276
19.
ChattopadhyayAKwartlerCSKawKLiYKawAChenJet alCholesterol-induced phenotypic modulation of smooth muscle cells to macrophage/fibroblast-like cells is driven by an unfolded protein response.Arterioscler Thromb Vasc Biol. (2021) 41:302–16. 10.1161/ATVBAHA.120.315164
20.
YapCMieremetAde VriesCJMMichaDde WaardV. Six shades of vascular smooth muscle cells illuminated by klf4 (krüppel-like factor 4).Arterioscler Thromb Vasc Biol. (2021) 41:2693–707. 10.1161/ATVBAHA.121.316600
21.
ChandranRRXieYGallardo-VaraEAdamsTGarcia-MilianRKabirIet alDistinct roles of klf4 in mesenchymal cell subtypes during lung fibrogenesis.Nat Commun. (2021) 12:7179. 10.1038/s41467-021-27499-8
22.
SunDDingDLiQXieMXuYLiuX. The preventive and therapeutic effects of aav1-klf4-shrna in cigarette smoke-induced pulmonary hypertension.J Cell Mol Med. (2021) 25:1238–51. 10.1111/jcmm.16194
23.
SunDLiQDingDLiXXieMXuYet alRole of krüppel-like factor 4 in cigarette smoke-induced pulmonary vascular remodeling.Am J Transl Res. (2018) 10:581–91.
24.
RoushGCSicaDA. Diuretics for hypertension: a review and update.Am J Hypert. (2016) 29:1130–7. 10.1093/ajh/hpw030
25.
MorrisRCSchmidlinOSebastianATanakaMKurtzTW. Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension.Circulation. (2016) 133:881–93. 10.1161/CIRCULATIONAHA.115.017923
26.
KawarazakiWFujitaT. Kidney and epigenetic mechanisms of salt-sensitive hypertension.Nat Rev Nephrol. (2021) 17:350–63. 10.1038/s41581-021-00399-2
27.
EllisonDHWellingP. Insights into salt handling and blood pressure.New England J Med. (2021) 385:1981–93. 10.1056/NEJMra2030212
28.
TerkerASZhangCMcCormickJALazelleRAZhangCMeermeierNPet alPotassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride.Cell Metab. (2015) 21:39–50. 10.1016/j.cmet.2014.12.006
29.
CuevasCASuXTWangMXTerkerASLinDHMcCormickJAet alPotassium sensing by renal distal tubules requires kir4.1.J Am Soc Nephrol. (2017) 28:1814–25. 10.1681/ASN.2016090935
30.
MarquesFZMackayCRKayeDM. Beyond gut feelings: how the gut microbiota regulates blood pressure.Nat Rev Cardiol. (2018) 15:20–32. 10.1038/nrcardio.2017.120
31.
MuralitharanRRJamaHAXieLPehASnelsonMMarquesFZ. Microbial peer pressure.Hypertension. (2020) 76:1674–87. 10.1161/HYPERTENSIONAHA.120.14473
32.
YanXJinJSuXYinXGaoJWangXet alIntestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension.Circ Res. (2020) 126:839–53. 10.1161/CIRCRESAHA.119.316394
33.
FergusonJFAdenLABarbaroNRVan BeusecumJPXiaoLSimmonsAJet alHigh dietary salt-induced dendritic cell activation underlies microbial dysbiosis-associated hypertension.JCI Insight. (2019) 5:e126241. 10.1172/jci.insight.126241
34.
WilckNMatusMGKearneySMOlesenSWForslundKBartolomaeusHet alSalt-responsive gut commensal modulates th17 axis and disease.Nature. (2017) 551:585–9. 10.1038/nature24628
35.
MarquesFZNelsonEChuP-YHorlockDFiedlerAZiemannMet alHigh-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice.Circulation. (2017) 135:964–77. 10.1161/CIRCULATIONAHA.116.024545
36.
MuralitharanRMarquesFZ. Diet-related gut microbial metabolites and sensing in hypertension.J Hum Hypertens. (2021) 35:162–9. 10.1038/s41371-020-0388-3
37.
KarbachSHSchönfelderTBrandãoIWilmsEHörmannNJäckelSet alGut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction.J Am Heart Assoc. (2016) 5:e003698. 10.1161/JAHA.116.003698
38.
KayeDMShihataWAJamaHATsyganovKZiemannMKiriazisHet alDeficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease.Circulation. (2020) 141:1393–403. 10.1161/CIRCULATIONAHA.119.043081
39.
CheemaMUPluznickJL. Gut microbiota plays a central role to modulate the plasma and fecal metabolomes in response to angiotensin II.Hypertension. (2019) 74:184–93. 10.1161/HYPERTENSIONAHA.119.13155
40.
NatarajanNHoriDFlavahanSSteppanJFlavahanNABerkowitzDEet alMicrobial short chain fatty acid metabolites lower blood pressure via endothelial g protein-coupled receptor 41.Physiol Genomics. (2016) 48:826–34. 10.1152/physiolgenomics.00089.2016
41.
PluznickJLProtzkoRJGevorgyanHPeterlinZSiposAHanJet alOlfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation.Proc Natl Acad Sci USA. (2013) 110:4410–5. 10.1073/pnas.1215927110
42.
ZhengWZhaoSYinYZhangHNeedhamDMEvansEDet alHigh-throughput, single-microbe genomics with strain resolution, applied to a human gut microbiome.Science. (2022) 376:eabm1483. 10.1126/science.abm1483
43.
GraudalNAHubeck-GraudalTJurgensG. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride.Cochrane Database Syst Rev. (2020) 12:Cd004022. 10.1002/14651858.CD004022.pub5
44.
JacksonSLKingSMZhaoLCogswellME. Prevalence of excess sodium intake in the united states - nhanes, 2009-2012.MMWR Morb Mortal Wkly Rep. (2016) 64:1393–7. 10.15585/mmwr.mm6452a1
45.
HuangLTrieuKYoshimuraSNealBWoodwardMCampbellNRCet alEffect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials.BMJ. (2020) 368:m315. 10.1136/bmj.m315
46.
OparilS. Low sodium intake–cardiovascular health benefit or risk?N Engl J Med. (2014) 371:677–9. 10.1056/NEJMe1407695
47.
StromBLAndersonCAIxJH. Sodium reduction in populations: insights from the institute of medicine committee.JAMA. (2013) 310:31–2. 10.1001/jama.2013.7687
48.
TreasureJPlothD. Role of dietary potassium in the treatment of hypertension.Hypertension. (1983) 5:864–72. 10.1161/01.HYP.5.6.864
49.
FilippiniTNaskaAKasdagliMITorresDLopesCCarvalhoCet alPotassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials.J Am Heart Assoc. (2020) 9:e015719. 10.1161/JAHA.119.015719
50.
GreerRCMarklundMAndersonCAMCobbLKDalcinATHenryMet alPotassium-enriched salt substitutes as a means to lower blood pressure: benefits and risks.Hypertension. (2020) 75:266–74. 10.1161/HYPERTENSIONAHA.119.13241
51.
NealBWuYFengXZhangRZhangYShiJet alEffect of salt substitution on cardiovascular events and death.New England J Med. (2021) 385:1067–77. 10.1056/NEJMoa2105675
52.
NealBTianMLiNElliottPYanLLLabartheDRet alRationale, design, and baseline characteristics of the salt substitute and stroke study (ssass)-a large-scale cluster randomized controlled trial.Am Heart J. (2017) 188:109–17. 10.1016/j.ahj.2017.02.033
53.
ZhouBWebsterJFuL-YWangH-LWuX-MWangW-Let alIntake of low sodium salt substitute for 3years attenuates the increase in blood pressure in a rural population of north china — a randomized controlled trial.Int J Cardiol. (2016) 215:377–82. 10.1016/j.ijcard.2016.04.073
54.
SunHMaBWuXWangHZhouB. Long-term effect of salt substitute on all-cause and cardiovascular disease mortality: an exploratory follow-up of a randomized controlled trial.Front Cardiovasc Med. (2021) 8:645902. 10.3389/fcvm.2021.645902
55.
LiK-CHuangLTianMDi TannaGLYuJZhangXet alCost-effectiveness of a household salt substitution intervention: findings from 20,995 participants of the salt substitute and stroke study.Circulation. (2022) 145:1534–41. 10.1161/CIRCULATIONAHA.122.059573
56.
YuJThoutSRLiQTianMMarklundMArnottCet alEffects of a reduced-sodium added-potassium salt substitute on blood pressure in rural indian hypertensive patients: a randomized, double-blind, controlled trial.Am J Clin Nutr. (2021) 114:185–93. 10.1093/ajcn/nqab054
57.
LiuYChuHPengKYinXHuangLWuYet alFactors associated with the use of a salt substitute in rural china.JAMA Netw Open. (2021) 4:e2137745. 10.1001/jamanetworkopen.2021.37745
58.
te RietLvan EschJHMRoksAJMvan den MeirackerAHDanserAHJ. Hypertension.Circ Res. (2015) 116:960–75. 10.1161/CIRCRESAHA.116.303587
59.
Abdel GhafarMT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension.Steroids. (2020) 163:108701. 10.1016/j.steroids.2020.108701
60.
BollagWB. Regulation of aldosterone synthesis and secretion.Comput Physiol. (2014) 4:1017–55. 10.1002/cphy.c130037
61.
MichelJBGuettierCPhilippeMGalenFXCorvolPMénardJ. Active immunization against renin in normotensive marmoset.Proc Natl Acad Sci USA. (1987) 84:4346–50. 10.1073/pnas.84.12.4346
62.
MichelJBSayahSGuettierCNussbergerJPhilippeMGonzalezMFet alPhysiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin.Circulation. (1990) 81:1899–910. 10.1161/01.CIR.81.6.1899
63.
BjerreHLChristensenJBBuusNHSimonsenUSuJ. The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.J Hum Hypertens. (2019) 33:795–806. 10.1038/s41371-018-0149-8
64.
ZhaoQShenJLuJJiangQWangY. Clinical efficacy, safety and tolerability of aliskiren monotherapy (am): an umbrella review of systematic reviews.BMC Cardiovasc Disord. (2020) 20:179. 10.1186/s12872-020-01442-z
65.
TissotACMaurerPNussbergerJSabatRPfisterTIgnatenkoSet alEffect of immunisation against angiotensin II with cyt006-angqb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase II a study.Lancet. (2008) 371:821–7. 10.1016/S0140-6736(08)60381-5
66.
LiCYanXWuDZhangKLiangXPanYet alVaccine targeted alpha 1d-adrenergic receptor for hypertension.Hypertension. (2019) 74:1551–62. 10.1161/HYPERTENSIONAHA.119.13700
67.
ParatiGEslerM. The human sympathetic nervous system: its relevance in hypertension and heart failure.Eur Heart J. (2012) 33:1058–66. 10.1093/eurheartj/ehs041
68.
ManciaGGrassiG. The autonomic nervous system and hypertension.Circ Res. (2014) 114:1804–14. 10.1161/CIRCRESAHA.114.302524
69.
RondonMUPBLaterzaMCde MatosLDNJTrombettaICBragaAMWRovedaFet alAbnormal muscle metaboreflex control of sympathetic activity in never-treated hypertensive subjects*.Am J Hypertens. (2006) 19:951–7. 10.1016/j.amjhyper.2006.02.001
70.
KobeticMDBurchellAERatcliffeLEKNeumannSAdamsZHNolanRet alSympathetic-transduction in untreated hypertension.J Hum Hyperten. (2022) 36:24–31. 10.1038/s41371-021-00578-5
71.
HissenSLTaylorCE. Sex differences in vascular transduction of sympathetic nerve activity.Clin Auto Res. (2020) 30:381–92. 10.1007/s10286-020-00722-0
72.
MantaEKouremetiMKakouriNKasiakogiasAKonstantinidisDPapakonstantinouPet alCorrelations of attended and unattended blood pressure with sympathetic nervous system activity in essential hypertension.Eur Heart J. (2020) 41:2754. 10.1093/ehjci/ehaa946.2754
73.
KarioKKimBKAokiJWongAYLeeYHWongpraparutNet alRenal denervation in asia: consensus statement of the asia renal denervation consortium.Hypertension. (2020) 75:590–602. 10.1161/HYPERTENSIONAHA.119.13671
74.
ThomopoulosCBazoukisGTsioufisCManciaG. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials.J Hypertens. (2020) 38:1669–81. 10.1097/HJH.0000000000002523
75.
EhlersTSSverrisdottirYBangsboJGunnarssonTP. High-intensity interval training decreases muscle sympathetic nerve activity in men with essential hypertension and in normotensive controls.Front Neurosci. (2020) 14:841. 10.3389/fnins.2020.00841
76.
LaterzaMCde MatosLDTrombettaICBragaAMRovedaFAlvesMJet alExercise training restores baroreflex sensitivity in never-treated hypertensive patients.Hypertension. (2007) 49:1298–306. 10.1161/HYPERTENSIONAHA.106.085548
77.
SchlaichMPSchmiederREBakrisGBlankestijnPJBöhmMCampeseVMet alInternational expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension.J Am College Cardiol. (2013) 62:2031–45. 10.1016/j.jacc.2013.08.1616
78.
KrumHSchlaichMPSobotkaPABöhmMMahfoudFRocha-SinghKet alPercutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the symplicity htn-1 study.Lancet. (2014) 383:622–9. 10.1016/S0140-6736(13)62192-3
79.
EslerMDKrumHSobotkaPASchlaichMPSchmiederREBöhmM. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial.Lancet. (2010) 376:1903–9. 10.1016/S0140-6736(10)62039-9
80.
BhattDLKandzariDEO’NeillWWD’AgostinoRFlackJMKatzenBTet alA controlled trial of renal denervation for resistant hypertension.N Engl J Med. (2014) 370:1393–401. 10.1056/NEJMoa1402670
81.
PersuAMaesFRenkinJPathakA. Renal denervation in hypertensive patients: back to anatomy?Hypertension. (2020) 76:1084–6. 10.1161/HYPERTENSIONAHA.120.15834
82.
PapademetriouVTsioufisCDoumasM. Renal denervation and symplicity htn-3: “dubium sapientiae initium”(doubt is the beginning of wisdom).Circ Res. (2014) 115:211–4. 10.1161/CIRCRESAHA.115.304099
83.
CabreraCPNgFLNichollsHLGuptaABarnesMRMunroePBet alOver 1000 genetic loci influencing blood pressure with multiple systems and tissues implicated.Hum Mol Genet. (2019) 28:R151–61. 10.1093/hmg/ddz197
84.
EvangelouEWarrenHRMosen-AnsorenaDMifsudBPazokiRGaoHet alGenetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.Nat Genet. (2018) 50:1412–25.
85.
EhretGBFerreiraTChasmanDIJacksonAUSchmidtEMJohnsonTet alThe genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals.Nat Genet. (2016) 48:1171–84.
86.
GiriAHellwegeJNKeatonJMParkJQiuCWarrenHRet alTrans-ethnic association study of blood pressure determinants in over 750,000 individuals.Nat Genet. (2019) 51:51–62. 10.1038/s41588-018-0303-9
87.
KatoNLohMTakeuchiFVerweijNWangXZhangWet alTrans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.Nat Genet. (2015) 47:1282–93.
88.
MunroePBBarnesMRCaulfieldMJ. Advances in blood pressure genomics.Circ Res. (2013) 112:1365–79. 10.1161/CIRCRESAHA.112.300387
89.
SchmittADHuMJungIXuZQiuYTanCLet alA compendium of chromatin contact maps reveals spatially active regions in the human genome.Cell Rep. (2016) 17:2042–59. 10.1016/j.celrep.2016.10.061
90.
VauraFKaukoASuvilaKHavulinnaASMarsNSalomaaVet alPolygenic risk scores predict hypertension onset and cardiovascular risk.Hypertension. (2021) 77:1119–27. 10.1161/HYPERTENSIONAHA.120.16471
91.
RichardMAHuanTLigthartSGondaliaRJhunMABrodyJAet alDNA methylation analysis identifies loci for blood pressure regulation.Am J Hum Genet. (2017) 101:888–902.
92.
WangFDemuraMChengYZhuAKarashimaSYonedaTet alDynamic ccaat/enhancer binding protein-associated changes of DNA methylation in the angiotensinogen gene.Hypertension. (2014) 63:281–8. 10.1161/HYPERTENSIONAHA.113.02303
93.
BogdarinaIWelhamSKingPJBurnsSPClarkAJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension.Circ Res. (2007) 100:520–6. 10.1161/01.RES.0000258855.60637.58
94.
ParamasivamAVijayashree PriyadharsiniJRaghunandhakumarS. N6-adenosine methylation (m6a): a promising new molecular target in hypertension and cardiovascular diseases.Hypertens Res. (2020) 43:153–4. 10.1038/s41440-019-0338-z
95.
MoXBLeiSFZhangYHZhangH. Examination of the associations between m(6)a-associated single-nucleotide polymorphisms and blood pressure.Hypertens Res. (2019) 42:1582–9. 10.1038/s41440-019-0277-8
96.
LiangM. Epigenetic mechanisms and hypertension.Hypertension. (2018) 72:1244–54. 10.1161/HYPERTENSIONAHA.118.11171
97.
ArifMSadayappanSBeckerRCMartinLJUrbinaEM. Epigenetic modification: a regulatory mechanism in essential hypertension.Hypertens Res. (2019) 42:1099–113. 10.1038/s41440-019-0248-0
98.
HarrisonDGCoffmanTMWilcoxCS. Pathophysiology of hypertension: the mosaic theory and beyond.Circ Res. (2021) 128:847–63. 10.1161/CIRCRESAHA.121.318082
99.
MocanORădulescuDBuzduganECozmaALeucutaDCBogdanSAet alAssociation between polymorphisms of genes involved in the renin-angiotensin-aldosterone system and the adaptive morphological and functional responses to essential hypertension.Biomed Rep. (2021) 15:80. 10.3892/br.2021.1456
100.
CharoenPEu-AhsunthornwattanaJThongmungNJosePASritaraPVathesatogkitPet alContribution of four polymorphisms in renin-angiotensin-aldosterone-related genes to hypertension in a thai population.Int J Hypertens. (2019) 2019:4861081. 10.1155/2019/4861081
101.
ChandraSNarangRSreenivasVBhatiaJSalujaDSrivastavaK. Association of angiotensin II type 1 receptor (a1166c) gene polymorphism and its increased expression in essential hypertension: a case-control study.PLoS One. (2014) 9:e101502. 10.1371/journal.pone.0101502
102.
LiuZQiHLiuBLiuKWuJCaoHet alGenetic susceptibility to salt-sensitive hypertension in a han chinese population: a validation study of candidate genes.Hypertens Res. (2017) 40:876–84. 10.1038/hr.2017.57
103.
LevyDLarsonMGBenjaminEJNewton-ChehCWangTJHwangS-Jet alFramingham heart study 100k project: genome-wide associations for blood pressure and arterial stiffness.BMC Med Genet. (2007) 8:S3. 10.1186/1471-2350-8-S1-S3
104.
EikelisNMarquesFZHeringDMarusicPHeadGAWaltonASet alA polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension.J Hypertens. (2018) 36:1571–7. 10.1097/HJH.0000000000001736
105.
JiaGAroorARHillMASowersJR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness.Hypertension. (2018) 72:537–48. 10.1161/HYPERTENSIONAHA.118.11065
106.
NevesMFCunhaARCunhaMRGismondiRAOigmanW. The role of renin–angiotensin–aldosterone system and its new components in arterial stiffness and vascular aging.High Blood Pressure Cardiovas Prevent. (2018) 25:137–45. 10.1007/s40292-018-0252-5
107.
RietLTEschJHMVRoksAJMMeirackerAHVDDanserAHJ. Hypertension.Circ Res. (2015) 116:960–75.
108.
FinkGD. Sympathetic activity, vascular capacitance, and long-term regulation of arterial pressure.Hypertension. (2009) 53:307–12. 10.1161/HYPERTENSIONAHA.108.119990
109.
CarrizzoALenziPProcacciniCDamatoABiagioniFAmbrosioMet alPentraxin 3 induces vascular endothelial dysfunction through a p-selectin/matrix metalloproteinase-1 pathway.Circulation. (2015) 131:1495–1505; discussion 1505. 10.1161/CIRCULATIONAHA.114.014822
110.
GoettschCKjolbyMAikawaE. Sortilin and its multiple roles in cardiovascular and metabolic diseases.Arterioscler Thromb Vasc Biol. (2018) 38:19–25. 10.1161/ATVBAHA.117.310292
111.
Di PietroPCarrizzoASommellaEOlivetiMIacovielloLDi CastelnuovoAet alTargeting the asmase/s1p pathway protects from sortilin-evoked vascular damage in hypertension.J Clin Invest. (2022) 132:e146343. 10.1172/JCI146343
112.
JujicAMatthesFVanherleLPetzkaHOrho-MelanderMNilssonPMet alPlasma s1p (sphingosine-1-phosphate) links to hypertension and biomarkers of inflammation and cardiovascular disease: findings from a translational investigation.Hypertension. (2021) 78:195–209. 10.1161/HYPERTENSIONAHA.120.17379
113.
VecchioneCVillaFCarrizzoASpinelliCCDamatoAAmbrosioMet alA rare genetic variant of bpifb4 predisposes to high blood pressure via impairment of nitric oxide signaling.Sci Rep. (2017) 7:9706. 10.1038/s41598-017-10341-x
114.
DrewDAKatzRKritchevskySIxJHShlipakMGNewmanABet alSoluble klotho and incident hypertension.Clin J Am Soc Nephrol. (2021) 16:1502–11. 10.2215/CJN.05020421
115.
TanPPSHallDChilianWMChiaYCMohd ZainSLimHMet alExosomal micrornas in the development of essential hypertension and its potential as biomarkers.Am J Phys Heart Circ Phys. (2021) 320:H1486–97. 10.1152/ajpheart.00888.2020
116.
ZhangLQiHLiuZPengWJCaoHGuoCYet alConstruction of a cerna coregulatory network and screening of hub biomarkers for salt-sensitive hypertension.J Cell Mol Med. (2020) 24:7254–65. 10.1111/jcmm.15285
117.
SugimotoHMuraiHHamaokaTMukaiYInoueOOkabeYet alNovel index of arterial reflected waves, arterial velocity pulse index, relates to muscle sympathetic nerve activity independent of arterial pressure volume index in patients with hypertension.Eur Heart J. (2020) 41:2720. 10.1093/ehjci/ehaa946.2720
118.
SugimotoHMuraiHHiraiTHamaokaTMukaiYTokuhisaHet alAge differences in the association between arterial velocity pulse index and muscle sympathetic nerve activity in hypertensive patients.Eur Heart J. (2021) 42:2307. 10.1093/eurheartj/ehab724.2307
119.
MahfoudFTownsendRRKandzariDEKarioKSchmiederRETsioufisKet alChanges in plasma renin activity after renal artery sympathetic denervation.J Am Coll Cardiol. (2021) 77:2909–19. 10.1016/j.jacc.2021.04.044
120.
QinFLiJDaiYFZhongXGPanYJ. Renal denervation inhibits the renin-angiotensin-aldosterone system in spontaneously hypertensive rats.Clin Exp Hypertens. (2022) 44:83–92. 10.1080/10641963.2021.1996587
121.
QiuZChenXZhouYLinJDingDYangSet alTherapeutic vaccines against human and rat renin in spontaneously hypertensive rats.PLoS One. (2013) 8:e66420. 10.1371/journal.pone.0066420
122.
GardinerSMAutonTRDownhamMRSharpHLKempPAMarchJEet alActive immunization with angiotensin i peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin i in conscious rats.Br J Pharmacol. (2000) 129:1178–82. 10.1038/sj.bjp.0703178
123.
BrownMJColtartJGunewardenaKRitterJMAutonTRGloverJF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (pmd3117) in hypertensive subjects.Clin Sci. (2004) 107:167–73. 10.1042/CS20030381
124.
KoriyamaHNakagamiHNakagamiFOsakoMKKyutokuMShimamuraMet alLong-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats.Hypertension. (2015) 66:167–74. 10.1161/HYPERTENSIONAHA.114.04534
125.
SilvaAFTorresMDTSilvaLSAlvesFLde Sá PinheiroAAMirandaAet alAngiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction.Sci Rep. (2017) 7:14326. 10.1038/s41598-017-14642-z
126.
ChenXQiuZYangSDingDChenFZhouYet alEffectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals.Hypertension. (2013) 61:408–16. 10.1161/HYPERTENSIONAHA.112.201020
Summary
Keywords
essential hypertension, arterial stiffness, salt-sensitive, sympathetic dysregulation, genetics - clinical
Citation
Ma J and Chen X (2022) Advances in pathogenesis and treatment of essential hypertension. Front. Cardiovasc. Med. 9:1003852. doi: 10.3389/fcvm.2022.1003852
Received
26 July 2022
Accepted
26 September 2022
Published
14 October 2022
Volume
9 - 2022
Edited by
Guido Iaccarino, University of Naples Federico II, Italy
Reviewed by
Albino Carrizzo, University of Salerno, Italy; Fiordelisi Antonella, University of Naples Federico II, Italy
Updates
Copyright
© 2022 Ma and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaoping Chen, xiaopingchen23@163.com
This article was submitted to Hypertension, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.